Table 3 Response status and survival rates during gemcitabine plus Nab Paclitaxel treatment.
From: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
N= 218 (%) | |
|---|---|
Response status at 3 months (N= 218) | |
Complete radiological response | 3 (1.4) |
Partial response | 49 (22.5) |
Stable disease | 48 (22.0) |
Progressive disease | 118 (54.1) |
Response status at 6 months (N= 96) | |
Complete radiological response | 4 (4.1) |
Partial response | 16 (16.6) |
Stable disease | 27 (28.1) |
Progressive disease | 49 (51.2) |
PFS after first-line treatment (months) | 5.1 (4.3-6.0) |
OS after first-line treatment (months) | 8.6 (7.3-10.3) |
